Philadelphia Chromosome - 26 Studies Found
No longer available |
: Compassionate Use Ponatinib :
|
Completed |
: Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects : Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML) : 2011-06-07 :
|
Active, not recruiting |
: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI :
|
Active, not recruiting |
: Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia :
|
Completed |
: Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia : Leukemia : 2005-10-25 :
|
Completed |
: Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias : Chronic Myelogenous Leukemia : 2008-12-17 : Drug: SKI-606 (Bosutinib) Formulation: 100 mg Capsule for |
Completed |
: Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion : Philadelphia Chromosome-positive Chronic Myelocytic Leukemia : 2009-08-26 : Procedure: Stem cell transplantation Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4 |
Completed |
: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias : Chronic Myeloid Leukemia : 2005-12-02 : Drug: Bosutinib Part 1, starting dose 400 mg oral, daily d |
Recruiting |
: A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL :
|
Completed |
: Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy : Philadelphia Chromosome Positive Chronic Myelogenous Leukemia : 2011-10-14 : Drug: Nilotinib + LDE225 Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosi |